| Advanced
Heart Formula Protects Against Myocardial Damage, Ischemia
Cardiovascular disease (CVD) is a leading cause
of death in the United States. Over 71 million Americans currently
suffer from some form of heart disease, and one million people die
every year despite access to an extensive array of modern drugs
and surgical procedures. The situation in developing countries is
much worse, as the high expense of advanced Western medical options
severely restricts patient access to many contemporary treatments.
CardioPhase is a Chinese medicinal formula based
on traditional theories about restoration and improvement of heart
function. Developed over a ten-year period by a team of leading
medical researchers at China’s National Institute of Science,
CardioPhase has been shown to alleviate myocardial damage induced
by anoxia (lack of oxygen) and ischemia (lack of blood flow) to
heart tissues.
In addition to nourishing heart tissues and enhancing
hemodynamics (literally “blood dynamics”) CardioPhase
has been shown to improve the physical characteristics of blood
cells while supporting blood flow to the heart. CardioPhase has
also been shown to be safe for regular use, exhibiting virtually
no toxic effects in large and extended doses.
The lack of affordable treatments for heart disease posed serious
problems for China in the early 1980s. The country was in the midst
of an intense period of modernization as millions of rural workers
abandoned their traditional farms to work in newly built factories
and industrial parks. An unintended consequence of this unprecedented
migration was that, as workers left behind their traditional life-styles,
they also gave up their traditional foods and adopted a Westernized
diet high in calories, saturated fats and processed sugars. Not
surprisingly the outcome of this shift in dietary habits was a sudden
surge in the incidence of heart disease, and by 1989 a staggering
12 million people were dying from heart disease every year.
To cope with the crisis, in 1989 Chinese health
authorities drafted a team of leading scientists from the prestigious
National Academy of Science in Beijing and commissioned them to
develop a natural, inexpensive and non-intrusive solution for heart
disease. After a decade of intense research, the team introduced
CardioPhase, a unique herbal formula based on traditional Chinese
theories of restoration and improvement of heart function. After
passing a series of stringent animal and human trials, Cardio-Phase
was certified by the Academy of Sciences in 1999 for use in hospitals
as a primary treatment for a variety of cardiac disorders, including
chronic congestive heart failure.
Following its approval, ongoing clinical trials
across China continued to demonstrate statistically significant
results with CardioPhase. In particular, the formula was found to
alleviate myocardial damage induced by anoxia (lack of oxygen) and
ischemia (lack of blood flow) to heart tissues by lowering rates
of lipid peroxidation and increasing endogenous levels of sodium
oxide dismutase (SOD).
CardioPhase was also found to reduce pulmonary
arterial blood pressure, improve microcirculation, enhance cardiac
output and reduce clinical symptoms such as high blood pressure,
shortness of breath, angina, palpitations and dizziness.
Research Studies
Researchers treated 304 patients previously diagnosed with myocardial
damage and cardiac insufficiency. After receiving CardioPhase for
a period of six weeks, 100 patients (30%) were shown to be free
of previous clinical symptoms, including angina, arrhythmia, dizziness
and shortness of breath. The study authors noted that electrocardiogram
(ECG or EKG) scores for this group had returned to normal (healthy)
values.
An additional 189 subjects from the same study
(62%) showed signs of significant benefits, including improvements
in one or more symptoms and/or significant improvements in ECG/EKG
scores. Of the total of 304 subjects receiving CardioPhase, only
15 patients (less than 4%) failed to show signs of improvement.
Put in perspective, 95% of all participants experienced significant
improvement after only six weeks of treatment.
In summarizing their findings the study authors
noted that CardioPhase’s ability to enhance blood SOD activity
and reduce plasma LPO concentrations made it “an effective
agent for improving and restoring myocardial functions.” Noting
CardioPhase’s ability to reduce pulmonary arterial pressure
and pulmonary capillary wedge pressure, the researchers concluded
that “CardioPhase can be safely used for myocardial damage
caused by various organic cardiopathies.”
Myocardial ischemia occurs when blood flow to heart tissues is impaired,
reducing the supply of oxygen and damaging heart tissues. The condition
is usually caused by coronary artery disease. Animal experiments
had previously shown that Cardio-Phase improves cases of myocardial
ischemia by restoring myocardial microcirculation, enhancing myocardial
metabolism, raising serum levels of glutathione, and stimulating
oxidation-reduction to reduce free radical damage to protect heart
tissues and promote resistance to damage.
In this study researchers treated 52 patients
diagnosed with myocardial ischemia with CardioPhase. After four
weeks of treatment the researchers noted improvements in clinical
symptoms in 87% of the patients and improved electrocardiogram scores
in 42% the patients.
Researchers measured the hemodynamic effects of CardioPhase on 32
patients diagnosed with congestive heart failure (CHF). Baseline
readings of heart rate, blood pressure, mean right atrial pressure
(MRAP), mean pulmonary arterial pressure (MPAP), pulmonary wedge
pressure (PWP) and cardiac index (CI) readings were measured at
the start of the study and again every hour for eight hours following
treatment with CardioPhase.
The study revealed that CardioPhase reduced mean
right atrial pressure (MRAP) and pulmonary wedge pressure (PWP),
and improved the cardiac index (CI) (P<0.05) for a period of
4 hours after intake.
Researchers measured CardioPhase’s therapeutic effect on plasma
viscosity levels in 105 patients diagnosed with coronary artery
disease. After 40 days of treatment with CardioPhase all patients
showed statistically significant decreases in plasma viscosity.
Importantly, the subgroup of patients with elevated blood viscosity
also showed statistically significant decreases in plasma viscosity.
The study authors concluded that “our results indicate that
administration of CardioPhase can decrease plasma viscosity and
reduce the impact of this contributing factor on the progression
of coronary heart disease and eventual heart infarction.”
Researchers from the Cardiac Medicine Department of First Medical
College, Xi’an, conducted a clinical trial on 119 patients
diagnosed with coronary artery disease and myocardial damage caused
by other organic heart disease. The subjects, 65 males and 54 females,
received CardioPhase three times daily for a period of six weeks.
The study outcome showed that CardioPhase improved blood supply
and oxygen delivery to heart tissues, thereby reducing symptoms
such as angina and shortness of breath while improving electrocardiograms
(i.e., improved S-T segment depression, T wave flatness and inversion).
Researchers at Tianjin University of Traditional Chinese Medicine
treated 54 patients hospitalized with myocardial damage caused by
coronary artery disease. Patients were treated with CardioPhase
for a period of six weeks. At the conclusion of the trial 22 subjects
were diagnosed as recovered (i.e. clinical symptoms fully resolved
and electrocardiogram S-T segments and T waves returned to normal).
An additional 27 cases were deemed effective (i.e. symptoms were
partially improved, accompanied by improvement or normalization
of S-T segments and/or T waves). The total effective power for subjects
receiving CardioPhase was 90%. Clinical measurements also revealed
that CardioPhase increased SOD activity in red cells reduced LPO
in plasma, and normalized blood pressure levels.
The study authors report that their findings indicate that CardioPhase
is an effective treatment for myocardial ischemia and is superior
to propranolol, as demonstrated by the clearance of symptoms and
improved EKG scores. CardioPhase was found to benefit myocardial
ischemia and myocardial damage from many types of heart disease,
including myocarditis and coronary artery disease. In addition to
being superior to propranolol for relieving clinical symptoms and
improving ECG/ EKG readings, CardioPhase was also determined to
be free of side effects.
As a dietary supplement CardioPhase is generally
taken at a rate of 2 capsules, 3 times daily for optimal cardiovascular
support. For increased restorative effect intake may be increased
to 4 capsules, 3 times daily. |
